Biologika-Therapien in Österreich. Daten aus dem Österreichischen Biologika-Register BioReg

Zusammenfassung

In Österreich wurde vergleichsweise spät im Jahre 2009, das „Biologikaregister für entzündlich rheumatische Erkrankungen e. V.“, kurz BioReg, gegründet, mit den auch in anderen Ländern verfolgten Zielen, jene PatientInnen, die mit Biologika behandelt werden, hinsichtlich Tolerabilität und Effektivität zu dokumentieren. Aus dem Vereinsmodell ergibt sich die Freiwilligkeit der Teilnahme von Verschreibern, vergleichbar dem deutschen RABBIT Register. Mit Ende Mai 2017 waren insgesamt 2132 PatientInnen in die Datenbank eingeschlossen, davon waren 1157 PatientInnen mit Rheumatoider Arthritis (RA), 497 mit Spondylitis ankylosans (SpA), 401 mit Arthritis psoriatica (PsA) und 77 PatientInnen mit sonstigen rheumatischen Erkrankungen (SERE). Österreichs Rheumatologen initiieren – im Vergleich zu europäischen Kollegen – eine bDMARD-Therapie bereits bei RA Patienten mit hoch moderater Krankheitsaktivität. Der Behinderungsgrad der Patienten unter Biologika-Therapie kann insgesamt niedrig gehalten werden, was natürlich auch für den Erhalt der Berufsfähigkeit von Bedeutung ist. Außergewöhnliche Nebenwirkungen wurden bisher nicht beobachtet, die in BioReg aufgetretenen Nebenwirkungen entsprechen den bereits aus Studien bekannten. Die Häufigkeit der Anwendung der einzelnen Präparate ist durchaus mit der in Deutschland vergleichbar, auch die Retentionsraten sind nicht wesentlich unterschiedlich. Register, wie auch BioReg, zeigen den „heimlichen“ Normalfall der Behandlung von Patientinnen und Patienten mit entzündlich rheumatischen Erkrankungen und liefern damit einen wesentlichen Beitrag zur Qualitätssicherung.

Abstract

The Austrian Registry for Biologicals in the Treatment of Inflammatory Rheumatic Diseases, BioReg, was founded in 2009, which is relatively late compared to other countries. As elsewhere, the registry aims to document tolerability and efficacy. BioReg was founded as a non-profit association, which implies that the inclusion of patients is voluntary, as in the German RABBIT registry. At the end of May 2017, a total of 2,132 patients had been included in the data base, of whom 1,157 patients suffered from rheumatoid arthritis (RA), 497 from spondylitis ankylosans (SpA), 401 from psoriatic arthritis (PsA), and 77 from other rheumatic diseases (SERE). In comparison to European colleagues, rheumatologists in Austria initiate bDMARDs in RA patients at high moderate disease activity. Functionality of patients under biological treatment can be preserved, which of course exerts a positive impact on working ability. No unusual adverse events were observed; the reported side effects are the expected ones, well known from clinical trials. The prescription rates for the single compounds are comparable with those reported in the German RABBIT registry, and the retention rates are generally similar. Registries such as BioReg show the hidden normal situation for the treatment of patients with inflammatory rheumatic diseases, and specifically contribute to quality management.

Schlüsselwörter

Biologika - Rheumatoide Arthritis - Spondyloarthritiden - Register

Key words

Registry - Biologicals - Rheumatoid Arthritis - Spondylarthropathies

• Literatur

• 1 Silman A, Symmons D, Scott DG. et al. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003; 62 (Suppl. 02) ii28-ii29
• 2 Listing J, Strangfeld A, Rau R. et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 2006; 8: R66 Epub 2006 Apr 5
• 3 www.bioreg.at/
• 4 www.biologika-register.de/
• 5 Zamora NV, Christensen R, Goel N et al Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. J Rheumatol. 2017 pii: jrheum.161108. doi: 10.3899/jrheum.161108.[Epub ahead of print]
• 6 Schweyda HJ, Heiler J, Pieloth K. Monitor Versorgungsforschung 27 2017
• 7 Rintelen B, Zwerina J, Herold MD et al Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: Current practice of bDMARD therapy in Rheumatoid Arthritis in Austria. BMC Musculoskelet Disord 2016; 17: 358
• 8 Pincus T, Summey JA, Soraci Jr SA. et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 1346-1353
• 9 Leeb BF, Haindl PM, Maktari A. et al. Patient Centered Rheumatoid Arthritis Activity Assessment by a Modified RADAI. J Rheumatol 2008; 35: 1294-1299
• 10 Leeb BF, Haindl PM, Brezinschek HP. et al. Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA). BMC Musculoskelet Disord 2015; 16: 73
• 11 Garrett S, Jenkinson T, Kennedy LG. et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-2291
• 12 Prevoo ML, van’t Hof MA, Kuper HH. et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38: 44-48
• 13 Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol. 2007; 21: 663-675
• 14 Duclos M, Gossec L, Ruyssen-Witrand A. et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006; 33: 2433-2438
• 15 Virkki LM, Valleala H, Takakubo Y. et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis – a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol 2011; 30: 1447-1454
• 16 Hanserl A, Herold M, Eichbauer-Sturm G et al. Survival on TNF-blockers in Aian patients with Rheumatoid Arthritis (RA). How opportunities change therapeutic behaviours. Real-Life-Data from BioReg.Bologna, Conference: CORA 2017, DOI: 10.13140/RG.2.2.11052.87688
• 17 Listing J, Strangfeld A, Rau R. et al A Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 2006; 8: R66
• 18 Herold M, Eichbauer-Sturm G, Nothnagl T. et al. Good therapeutic response with biologics: remission is reality. data from the austrian bioreg registry. Ann Rheum Dis 2017; 76 (Suppl. 02) 1455 3-1456
• 19 Herold M, Eichbauer-Sturm G, Puchner R. et al. Commonplace though not approved – Monotherapy with Biologics. Data from the Austrian BioReg Registry. Ann Rheum Dis 2015; 74 (Suppl. 02) 486 1-486
• 20 Herold M, Eichbauer-Sturm G, Puchner R et al. The diagnostic delay in spodyloarthritis is improving. 3rd World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD), Montreal; April 2015
• 21 Prati C, Puyraveau M, Guillot X. et al. Wendling DDeaths Associated with Ankylosing Spondylitis in France from 1969 to 2009. J Rheumatol 2017; 44: 594-598
• 22 Frieder J, Kivelevitch D, Haugh I. et al. Anti-IL-23 and anti-IL-17 biologic agents for the treatment of immune-mediated inflammatory conditions. Clin Pharmacol Ther 2017; DOI: 10.1002/cpt.893. [Epub ahead of print]
• 23 Costa L, Del Puente A, Peluso R. et al. Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother 2017; 1-11 doi: 10.1080/14656566.2017.1378343 [Epub ahead of print]
• 24 Thomas E, Symmons DP, Brewster DH. et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: A 20 year followup study. J Rheumatol 2003; 30: 958-965
• 25 Singh JA, Wells GA, Christensen R. et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; CD008794 doi: 10.1002/14651858.CD008794.pub2 Review
• 26 England BR, Sayles H, Michaud K. et al. Cause-Specific mortality in male US veterans with rheumatoid. Arthr Care Res (Hoboken). 2016; 68: 36-45